Eli Lilly

Lilly expands partnership with Novast for branded generics

Thursday, June 14, 2012 02:53 PM

In support of its commitment to maximize growth opportunities in China, Eli Lilly has increased its network of manufacturing capabilities in this key emerging market country through an expanded collaboration with Novast Laboratories.

More... »

Lilly launches trial-finding mobile app for cancer patients

Friday, June 1, 2012 03:49 PM

Eli Lilly’s cancer division, Lilly Oncology, has launched a searchable clinical trial mobile application for oncology healthcare professionals.

More... »

Teralys Capital, Lilly invest in new $150 million fund for life sciences

Wednesday, May 30, 2012 10:36 AM

Teralys Capital has invested $65 million, along with other amounts from Eli Lilly and other partners, in TVM Life Science Ventures VII, which closed on an initial size of $150 million.

More... »

Lilly reports positive data in phase II diabetes study of dulaglutide

Friday, May 25, 2012 01:16 PM

Eli Lilly’s investigational drug dulaglutide, a long-acting glucagon-like peptide 1 (GLP-1) analog being studied as a once-weekly treatment for type 2 diabetes, met its primary endpoint of non-inferiority for mean 24-hour systolic blood pressure (SBP, or pressure while the heart contracts) after 16 weeks.

More... »

NIH launches collaborative program to spur therapeutic development

Friday, May 4, 2012 08:02 AM

The National Institutes of Health (NIH) has unveiled a collaborative program, Discovering New Therapeutic Uses for Existing Molecules, that will match researchers with a selection of pharmaceutical industry compounds to help scientists explore new treatments for patients.

More... »

Report: Pharmaceutical market grew by 5.3% in 2011

Friday, April 20, 2012 12:29 PM

Decision Resources, a research and advisory firm for pharmaceutical and healthcare issues, found that in 2011, the global pharmaceutical market, in dollar terms, benefitted significantly from positive currency effects.

More... »

Vanda lands exclusive world-wide license for VLY-686 from Lilly

Monday, April 16, 2012 11:40 AM

Vanda Pharmaceuticals, a biopharmaceutical company focused on central nervous system disorders, has acquired an exclusive world-wide license from Eli Lilly to develop and commercialize a small molecule neurokinin 1 receptor (NK-1R) antagonist for all human indications.

More... »

FDA approves Lilly’s Amyvid to detect Alzheimer's

Monday, April 9, 2012 11:53 AM

The FDA has approved Amyvid, a radioactive diagnostic agent indicated for brain imaging of beta-amyloid plaques associated with Alzheimer’s Disease and other cognitive decline, according to Eli Lilly and Avid Radiopharmaceuticals, a wholly owned subsidiary of Lilly.

More... »

Daiichi forms diabetes alliance with NGM Biopharma

Friday, March 30, 2012 03:07 PM

Tokyo-based Daiichi Sankyo has formed a partnership with San Francisco-based NGM Biopharmaceuticals to research and develop new treatments for diabetes.

More... »

Europe approves Byetta with basal insulin for T2D

Monday, March 26, 2012 02:47 PM

The European Commission has granted Amylin Pharmaceuticals and Eli Lilly marketing authorization for Byetta (exenatide twice-daily) as an adjunctive therapy to basal insulin for the treatment of type 2 diabetes (T2D).

More... »